search
Back to results

Eban II: Intervention for HIV Sero-Discordant Couples

Primary Purpose

Sexually Transmitted Diseases, Disease Transmission, Infectious, Safe Sex

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Risk Reduction
Sponsored by
University of California, Los Angeles
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Sexually Transmitted Diseases focused on measuring Implementation, HIV, serodiscordant couples, African American, Cultural congruency

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Must be in a relationship with study partner for at least 3 months
  • Both partners must be 18 years or older
  • At least one partner must identify as African American/Black
  • One partner must be HIV positive and one partner must be HIV negative
  • Must be a heterosexual couple (one biological female and one biological man)
  • Not currently expecting a child and not planning on having children within the year.

Exclusion Criteria:

  • Less than 18 years old
  • No partner
  • Couple is not heterosexual
  • Insufficient relationship length/commitment
  • No reported incidents of unprotected intercourse in the past 90 days
  • Neither partner is African American/Black
  • One/both partners unaware of others HIV status
  • Couple is not serodiscordant
  • One/both partners reported partner violence
  • HIV diagnosis received recently (less than 3 months)
  • One/both partners participated in a HIV Risk Reduction study within the past 12 months

Sites / Locations

  • Tarzana Treatment Centers
  • AIDS Project Los Angeles
  • AIDS Healthcare Foundation
  • O.A.S.I.S. Clinic
  • HIV Education & Prevention Project of Alameda CountyRecruiting
  • CAL-PEP
  • Allen Temple
  • Women Organized to Respond to Life-Threatening Disease

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Risk Reduction

Waitlist

Arm Description

The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following: Provide HIV and STI test results First Interview Attend 8 sessions - 1 session per week Second interview occurs immediately following the 8th session with HIV and STI tests Third interview occurs 3 months after the 8th session with HIV and STI tests

The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention. Provide HIV and STI test results First Interview No sessions for 8 weeks Second interview and proof of HIV and STI status occurs after the 8 weeks from when you were enrolled Third interview occurs 3 months after the 8th session with HIV and STI tests The Waitlist Group will then be invited to participate in the Risk Reduction group activities. Attend 8 sessions - 1 session per week Fourth interview occurs immediately after the 8th session with HIV and STI tests Fifth interview occurs 3 months after the 8th session with HIV and STI tests

Outcomes

Primary Outcome Measures

Safe Sex
Proportion of unprotected acts of sex.

Secondary Outcome Measures

Full Information

First Posted
April 8, 2013
Last Updated
February 8, 2016
Sponsor
University of California, Los Angeles
Collaborators
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT01829282
Brief Title
Eban II: Intervention for HIV Sero-Discordant Couples
Official Title
Implementing Eban II: An Evidence-Based Intervention for HIV Sero-Discordant Couples
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Unknown status
Study Start Date
July 2012 (undefined)
Primary Completion Date
April 2017 (Anticipated)
Study Completion Date
June 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Los Angeles
Collaborators
National Institute of Mental Health (NIMH)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study focuses on the implementation of an evidence-based HIV risk reduction intervention for HIV-serodiscordant, heterosexual African American couples ("Eban II") in two geographic areas (Northern and Southern California - roughly, Alameda and Los Angeles Counties) that have a high prevalence of HIV infection and risk conditions among African Americans. The Specific Aims are as follows: To evaluate implementation of Eban for HIV serodiscordant African American couples in 10 CBOs in California. To do this, we will document the implementation process and identify barriers and facilitators to Eban's adoption and use by the CBOs. We will interview 200 staff at CBOs to obtain this information. To evaluate the effect of Eban on behavioral and biological outcomes among 180 couples, specifically incidents of protected sex, proportion of condom use, and incident sexually transmitted infections. Eban will be assessed using a randomized delayed enrollment (waitlist) control design to evaluate the impact of treatment on outcomes at posttest and 3-month follow-up (i.e., at these 10 CBOs, Eban will be conducted and offered to couples and evaluated for effectiveness - that is, how well it works in the real world.) To determine the cost-effectiveness of implementation of Eban, based on implementation costs and potential cost savings.
Detailed Description
The HIV/AIDS epidemic continues to disproportionately affect African Americans. The rate of HIV among African American men is six times the rate for White men and the rate among African American women is almost 15 times the rate for White women. An estimated 56,300 new HIV cases was reported in 2006, of which 49% were among African Americans and 80% were from heterosexual transmission. Sexually transmitted infections (STIs) also disproportionately affect African Americans, further increasing the risk for HIV transmission. Despite the fact that HIV and STIs are primarily transmitted in the context of relationships, few interventions address HIV risk in couples. Furthermore, few evidence-based HIV prevention interventions have been implemented in community-based organizations (CBOs). Thus, there is a substantial need to strengthen the availability and use of relationship oriented prevention interventions in community-based treatment settings. This study focuses on the implementation of an evidence-based HIV risk reduction intervention for HIV-serodiscordant, heterosexual African American couples ("Eban II") in two geographic areas (Northern and Southern California - roughly, Alameda and Los Angeles Counties) that have a high prevalence of HIV infection and risk conditions among African Americans. This study builds upon the multi-site, NIMH-funded "Eban" (a Yoruba term for "fence") trial, which tested this culturally congruent intervention versus a control condition among 535 heterosexual HIV serodiscordant couples in four cities. Couples in the intervention had significantly reduced incidents of unprotected sex and an increased proportion of condom use compared to couples in the control condition. Statistical projections from that study suggest that if Eban participants had not received the intervention, six female and four males would have been infected in one year, and 25 females and 15 males would have become HIV-infected in the next 5 years. Based on these successful outcomes in a controlled trial, it is now appropriate to test the effectiveness of the intervention as delivered in community-based setting. Thus, we propose to conduct a study of implementation - a study of methods to promote the uptake of Eban into community-based organizations (CBOs). The Specific Aims are as follows: To evaluate implementation of Eban for HIV serodiscordant African American couples in 10 CBOs in California. To do this, we will document the implementation process and identify barriers and facilitators to Eban's adoption and use by the CBOs. We will interview 200 staff at CBOs to obtain this information. To evaluate the effect of Eban on behavioral and biological outcomes among 180 couples, specifically incidents of protected sex, proportion of condom use, and incident sexually transmitted infections. Eban will be assessed using a randomized delayed enrollment (waitlist) control design to evaluate the impact of treatment on outcomes at posttest and 3-month follow-up (i.e., at these 10 CBOs, Eban will be conducted and offered to couples and evaluated for effectiveness - that is, how well it works in the real world.) To determine the cost-effectiveness of implementation of Eban, based on implementation costs and potential cost savings. So please note, there are essentially two levels to this study -- first to see how well community agencies can implement or take up and execute the intervention (thus, the interviews with staff) - and the second, to see how effective Eban is in real world setting. We know it was highly effective in a controlled study but now we need to test how well it works in the "real" world(thus, the testing of the intervention with 180 couples). While doing this, we will also be examining the cost-effectiveness of the intervention in the "real" world setting.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sexually Transmitted Diseases, Disease Transmission, Infectious, Safe Sex, HIV
Keywords
Implementation, HIV, serodiscordant couples, African American, Cultural congruency

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Risk Reduction
Arm Type
Experimental
Arm Description
The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following: Provide HIV and STI test results First Interview Attend 8 sessions - 1 session per week Second interview occurs immediately following the 8th session with HIV and STI tests Third interview occurs 3 months after the 8th session with HIV and STI tests
Arm Title
Waitlist
Arm Type
Active Comparator
Arm Description
The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention. Provide HIV and STI test results First Interview No sessions for 8 weeks Second interview and proof of HIV and STI status occurs after the 8 weeks from when you were enrolled Third interview occurs 3 months after the 8th session with HIV and STI tests The Waitlist Group will then be invited to participate in the Risk Reduction group activities. Attend 8 sessions - 1 session per week Fourth interview occurs immediately after the 8th session with HIV and STI tests Fifth interview occurs 3 months after the 8th session with HIV and STI tests
Intervention Type
Behavioral
Intervention Name(s)
Risk Reduction
Primary Outcome Measure Information:
Title
Safe Sex
Description
Proportion of unprotected acts of sex.
Time Frame
within 3 months of completion of the intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Must be in a relationship with study partner for at least 3 months Both partners must be 18 years or older At least one partner must identify as African American/Black One partner must be HIV positive and one partner must be HIV negative Must be a heterosexual couple (one biological female and one biological man) Not currently expecting a child and not planning on having children within the year. Exclusion Criteria: Less than 18 years old No partner Couple is not heterosexual Insufficient relationship length/commitment No reported incidents of unprotected intercourse in the past 90 days Neither partner is African American/Black One/both partners unaware of others HIV status Couple is not serodiscordant One/both partners reported partner violence HIV diagnosis received recently (less than 3 months) One/both partners participated in a HIV Risk Reduction study within the past 12 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alicia M Eccles, MPH
Phone
310-794-9227
Email
aeccles@mednet.ucla.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gail E Wyatt, PhD
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
John Williams, MD
Organizational Affiliation
University of California, Los Angeles
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Brian Mittman, PhD
Organizational Affiliation
VA Office of Research and Development
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Alison Hamilton, PhD
Organizational Affiliation
University of California, Los Angeles
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Hector Myers, PhD
Organizational Affiliation
University of California, Los Angeles
Official's Role
Study Director
Facility Information:
Facility Name
Tarzana Treatment Centers
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
AIDS Project Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90005
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
AIDS Healthcare Foundation
City
Los Angeles
State/Province
California
ZIP/Postal Code
90015
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
O.A.S.I.S. Clinic
City
Los Angeles
State/Province
California
ZIP/Postal Code
90059
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
HIV Education & Prevention Project of Alameda County
City
Oakland
State/Province
California
ZIP/Postal Code
94601
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Melissa Struzzo, MPH
Email
mstruzzo@casasegura.org
Facility Name
CAL-PEP
City
Oakland
State/Province
California
ZIP/Postal Code
94608
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Allen Temple
City
Oakland
State/Province
California
ZIP/Postal Code
94612
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Women Organized to Respond to Life-Threatening Disease
City
Oakland
State/Province
California
ZIP/Postal Code
94612
Country
United States
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Learn more about this trial

Eban II: Intervention for HIV Sero-Discordant Couples

We'll reach out to this number within 24 hrs